Prognostic significance of pretreatment VEGF, survivin, and Smac/DIABLO serum levels in patients with serous ovarian carcinoma

Tumor Biology

Volumn 36, Issue 6, 2015, Pages 4157-4165

  Dobrzycka, Bozena ^a   Mackowiak Matejczyk, Beata ^b   Terlikowska, Katarzyna Maria ^a   Kulesza Bronczyk, Bozena ^a   Kinalski, Maciej ^c   Terlikowski, Slawomir Jerzy ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b Oncology Center of Bialystok   (Poland)

^c Provincial Hospital in Bialystok   (Poland)

Author keywords

Prognostic factors; Serous ovarian carcinoma; Smac DIABLO; Survivin; VEGF

Indexed keywords

ANTINEOPLASTIC AGENT; PLATINUM COMPLEX; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SURVIVIN; VASCULOTROPIN; BIRC5 PROTEIN, HUMAN; DIABLO PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; MITOCHONDRIAL PROTEIN; SIGNAL PEPTIDE; TUMOR MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE FREE SURVIVAL; EARLY DIAGNOSIS; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY CARCINOMA; OVERALL SURVIVAL; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SURVIVIN BLOOD LEVEL; VASCULOTROPIN BLOOD LEVEL; APOPTOSIS; BLOOD; CYSTADENOCARCINOMA; GENETICS; MALE; MIDDLE AGED; MITOCHONDRION; OVARY TUMOR; PATHOLOGY; PREOPERATIVE PERIOD; PROGNOSIS;

ADULT; APOPTOSIS; BIOMARKERS, TUMOR; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MIDDLE AGED; MITOCHONDRIA; MITOCHONDRIAL PROTEINS; OVARIAN NEOPLASMS; PREOPERATIVE PERIOD; PROGNOSIS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84938844133     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3050-x     Document Type: Article

References (38)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 21 August 2014.
2. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–403.
3. Reports based on data of National Cancer Registry. The Maria Sklodowska-Curie Memorial Cancer Center. Department of Epidemiology and Cancer Prevetion, National Cancer Registry 2011 [http://epid.coi.waw.pl/krn].
4. Legge F, Ferrandina G, Salutari V, Scambia G. Biological characterization of ovarian cancer: prognostic and therapeutic implications. Ann Oncol. 2005;16 Suppl 4:iv95–101.
5. Adams JM, Cory S. Life-or-death decisions by the Bcl-2 protein family. Trends Biochem Sci. 2001;26:61–6.
6. Martinez-Ruiz G, Maldonado V, Ceballos-Cancino G, Grajeda JP, Melendez-Zajgla J. Role of Smac/DIABLO in cancer progression. J Exp Clin Cancer Res. 2008;27:48. doi:10.1186/1756-9966-27-48.
7. Cheung CH, Huang CC, Tsai FY, Lee JY, Cheng SM, Chang YC, et al. Survivin-biology and potential as a therapeutic target in oncology. Onco Targets Ther. 2013;6:1453–62.
8. Mita AC, Mita MM, Nawrocki ST, Giles FJ. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin Cancer Res. 2008;14:5000–5.
9. Yu L, Deng L, Li J, Zhang Y, Hu L. The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol. 2013;128(2):391–6.
10. Mahner S, Woelber L, Eulenburg C, Schwarz J, Carney W, Jaenicke F, et al. TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients. BMC Cancer. 2010;10:139. doi:10.1186/1471-2407-10-139.
11. Benedet JL, Bender H, Jones H, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers FIGO Committee on Gynecologic Oncology. Int J Gynecol Obstet. 2000;70:209–62.
12. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92(3):205–16.
13. Rustin GJ, Vergote I, Eisenhauer E, Pujade-Lauraine E, Quinn M, Thigpen T, et al. Gynecological Cancer Intergroup. Definitions for response and progression in ovarian cancer clinical trials incorporating RECIST 1.1 and CA 125 agreed by the Gynecological Cancer Intergroup (GCIG). Int J Gynecol Cancer. 2011;21(2):419–23.
14. Friedlander M, Butow P, Stockler M, Gainford C, Martyn J, Oza A, et al. Symptom control in patients with recurrent ovarian cancer: measuring the benefit of palliative chemotherapy in women with platinum refractory/resistant ovarian cancer. Int J Gynecol Cancer. 2009;19 Suppl 2:S44–8.
15. No JH, Jeon YT, Kim YB, Song YS. Quantitative detection of serum survivin and its relationship with prognostic factors in ovarian cancer. Gynecol Obstet Invest. 2011;71(2):136–40.
16. Khan S, Bennit HF, Turay D, Perez M, Mirshahidi S, Yuan Y, et al. Early diagnostic value of survivin and its alternative splice variants in breast cancer. BMC Cancer. 2014;14:176. doi:10.1186/1471-2407-14-176.
17. Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anti-cancer therapy. Cancer Treat Rev. 2009;35(7):553–62.
18. Lawicki S, Będkowska GE, Gacuta-Szumarska E, Szmitkowski M. The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors. J Ovarian Res. 2013;6(1):45. doi:10.1186/1757-2215-6-45.
19. Lee JK, Hong YJ, Han CJ, Hwang DY, Hong SI. Clinical usefulness of serum and plasma vascular endothelial growth factor in cancer patients: which is the optimal specimen? Int J Oncol. 2000;17(1):149–52.
20. Tempfer C, Obermair A, Hefler L, Haeusler G, Gitsch G, Kainz C. Vascular endothelial growth factor serum concentrations in ovarian cancer. Obstet Gynecol. 1998;92(3):360–3.
21. Gadducci A, Ferdeghini M, Fanucchi A, Annicchiarico C, Ciampi B, Prontera C, et al. Serum preoperative vascular endothelial growth factor (VEGF) in epithelial ovarian cancer: relationship with prognostic variables and clinical outcome. Anticancer Res. 1999;19(2B):1401–5.
22. Chen CA, Cheng WF, Lee CN, Chen TM, Kung CC, Hsieh FJ, et al. Serum vascular endothelial growth factor in epithelial ovarian neoplasms: correlation with patient survival. Gynecol Oncol. 1999;74(2):235–40.
23. Oehler MK, Caffier H. Prognostic relevance of serum vascular endothelial growth factor in ovarian cancer. Anticancer Res. 2000;20(6D):5109–12.
24. Cooper BC, Ritchie JM, Broghammer CL, Coffin J, Sorosky JI, Buller RE, et al. Preoperative serum vascular endothelial growth factor levels: significance in ovarian cancer. Clin Cancer Res. 2002;8(10):3193–7.
25. Harlozinska A, Sedlaczek P, Kulpa J, Grybos M, Wójcik E, Van Dalen A, et al. Vascular endothelial growth factor (VEGF) concentration in sera and tumor effusions from patients with ovarian carcinoma. Anticancer Res. 2004;24(2C):1149–57.
26. Hefler LA, Zeillinger R, Grimm C, Sood AK, Cheng WF, Gadducci A, et al. Preoperative serum vascular endothelial growth factor as a prognostic parameter in ovarian cancer. Gynecol Oncol. 2006;103(2):512–7.
27. Bandiera E, Franceschini R, Specchia C, Bignotti E, Trevisiol C, Gion M, et al. Prognostic significance of vascular endothelial growth factor serum determination in women with ovarian cancer. ISRN Obstet Gynecol. 2012;2012:245756. doi:10.5402/2012/245756.
28. Sui L, Dong Y, Watanabe Y, Yamaguchi F, Sugimoto K, Tokuda M. Alteration and clinical relevance of PTEN expression and its correlation with survivin expression in epithelial ovarian tumors. Oncol Rep. 2006;15:773–8.
29. Liguang Z, Peishu L, Hongluan M, Hong J, Rong W, Wachtel MS, et al. Survivin expression in ovarian cancer. Exp Oncol. 2007;29:121–5.
30. Chen L, Liang L, Yan X, Liu N, Gong L, Pan S, et al. Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer. Int J Gynecol Cancer. 2013;23(2):256–63.
31. Qian X, Xi X, Li L. Nuclear survivin is associated with malignant potential in epithelial ovarian carcinoma. Appl Immunohistochem Mol Morphol. 2011;19(2):126–32.
32. Guney N, Soydine HO, Derin D, Tas F, Camlica H, Duranyildiz D, et al. Serum and urine survivin levels in breast cancer. Med Oncol. 2006;23(3):335–9.
33. Chang JT, Wong FH, Liao CT, Chen IH, Wang HM, Cheng AJ. Enzyme immunoassay for serum autoantibody to survivin and its findings in head-and-neck cancer patients. Clin Chem. 2004;50(7):1261–4.
34. Kehinde EO, Maghrebi MA, Anim JT. The importance of determining the aggressiveness of prostate cancer using serum and tissue molecular markers. Can J Urol. 2008;15(2):3967–74.
35. Song Z, Yao X, Wu M. Direct interaction between survivin and Smac/DIABLO is essential for the anti-apoptotic activity of survivin during taxol-induced apoptosis. J Biol Chem. 2003;278(25):23130–40.
36. Dobrzycka B, Terlikowski SJ, Bernaczyk PS, Garbowicz M, Niklinski J, Chyczewski L, et al. Prognostic significance of smac/DIABLO in endometrioid endometrial cancer. Folia Histochem Cytobiol. 2010;48(4):678–81.
37. Sekimura A, Konishi A, Mizuno K, Kobayashi Y, Sasaki H, Yano M, et al. Expression of Smac/DIABLO is a novel prognostic marker in lung cancer. Oncol Rep. 2004;11(4):797–802.
38. Mizutani Y, Katsuoka Y, Bonavida B. Low circulating serum levels of second mitochondria-derived activator of caspase (Smac/DIABLO) in patients with bladder cancer. Int J Oncol. 2012;40(4):1246–50.